Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

Last updated: February 13, 2014
Sponsor: Hordinsky, Maria K., MD
Overall Status: Completed

Phase

4

Condition

Hair Loss

Alopecia

Treatment

N/A

Clinical Study ID

NCT00176943
0009M64941
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Must be in good health.

  • No topical or systemic treatment for alopecia areata for at least 2 weeks prior tostudy initiation.

  • Must be at least 18 years of age and older

  • Will have to have extensive scalp alopecia areata (>95% involvement) of less than 2years duration.

  • Willing to refrain from other alopecia areata treatments during the course of thestudy.

  • Will have to agree to shampoo their scalp daily with Free and Clear shampoo.Participant in "Aldara for the Treatment of Extensive Alopecia Areata" study.

Exclusion

Exclusion Criteria:

  • History of any illness or condition that in the opinion of the investigator mightconfound the results of the study or pose additional risk to the patient

  • Significant abnormalities on screening clinical evaluation.

  • Previous use of Aldara Cream 5%.

  • A history of drug or alcohol abuse.

  • Use of UV radiation including tanning beds and PUVA therapy for treatment of acne,psoriasis, or any other skin condition within 2 months prior to study initiation.

  • Use of systemic or topical glucocorticoids, corticosteroids, estrogenic,progestogenic, androgenic or antiandrogen drugs, cyclosporine, FK506 or immunotherapywith DNCB,SADBE or DCP within 6 months of study initiation.

  • Alterations in thyroid medication within 6 weeks of study initiation. Pregnant ornursing females. Not participating in the "Aldara for the Treatment of ExtensiveAlopecia Areata" study.

Study Design

Total Participants: 20
Study Start date:
October 01, 2000
Estimated Completion Date:
August 31, 2002

Study Description

We will examine how the application of Aldara Cream 5% daily for 6 months will affect the hair follicle and the inflammation present in the skin of patients with alopecia areata. In the study we will obtain additional scalp biopsies to examine how the drug affects the quality and state of activity of the immune cells in the biopsy specimens. This type of information will provide data about the behavior of these inflammatory cells in mediating the hair loss associated with alopecia areata and how this behavior may be effected by Aldara Cream 5% treatment. Such information may be valuable to the successful management of alopecia areata.

Connect with a study center

  • University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.